Testicular cancer is the most frequent solid tumour in young men and accounts for 1% of newly diagnosed malignant tumours. Tumours are divided into seminomas and non-seminomas. Approximately 50% of patients are cured by orchiectomy alone, while the other half in addition will need chemotherapy or radiotherapy for metastatic disease. Survival in patients treated for metastatic disease depends on prognostic criteria. Patients treated with systemic therapy have an increased risk of subsequent cancer and cardiovascular disease, as argued in this review.